rituximab,epcoritamab,lenalidomide
abbvie,genmab
['epcoritamab', 'lymsm']
falci - epcor + r2 in 1l fl
- n=41, all unrx, mostly stage iii/iv
- crs all g1/2, 1 icans, some neutropenia seen
- orr 94%, cmr 86%
- med fu 8.1mo but dor very high so far.
clearly very active. need a randomised study. is 2y epcor needed - can this be reduced?
#ash22 #lymsm 
Associate Professor of Haematology and lymphoma specialist at Oxford Cancer and Haematology centre. Christian, husband and father.